Methadone: profile and news

Adjuvant Taxotere® and Herceptin® Effective for Breast Cancer ...  07 Mar 2006
Researchers affiliated with the FinHer Study have reported that Taxotere® (docetaxel) is superior to Navelbine® (vinorelbine) when given in addition to 5-FU ... - Cancer Consultants (press release),

Taxotere® and Novantrone® Sequence Evaluated as Initial ...  Feb 22, 2006
According to results recently published in the journal Cancer, initial chemotherapy treatment with the agent Taxotere® (docetaxel) followed by Novantrone ... - Cancer Consultants (press release),

Recurrence-Free Survival Improved with Taxotere® Compared to ...  Feb 23, 2006
According to an article recently published in the New England Journal of Medicine, treatment with the chemotherapy agent Taxotere® (docetaxel) improves ... - Cancer Consultants (press release),

Neoadjuvant Herceptin® plus Taxotere® Promising in Early Breast ...  Feb 24, 2006
...recently published in the Annals of Oncology, preoperative (neoadjuvant) therapy consisting of Herceptin® (trastuzumab) plus Taxotere® (docetaxel) appears ... - Cancer Consultants (press release),

Cell Genesys Reports Encouraging Follow-Up Survival Data From ...  Feb 27, 2006
...to the previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere(R) (docetaxel ... - International News Service,

GVAX® Vaccine Promising for Hormone-Refractory Prostate Cancer  Feb 28, 2006
These results compare favorably to the median survival of less than 19 months for the treatment of HRPC with Taxotere® (docetaxel)/prednisone, which is the ... - Cancer Consultants (press release),

Spectrum presents new satraplatin prostate cancer data  Feb 28, 2006
Seven patients in the study had hormone-refractory prostate cancer (HRPC), and all of the HRPC patients had received Sanofi-Aventis' Taxotere (docetaxel), with ... - Pharmaceutical Business Review

Cell Genesys Reports Encouraging Follow-Up Survival Data From ...  Feb 27, 2006
...previously published median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Taxotere® (docetaxel) chemotherapy ... - Yahoo! News (press release)

Spectrum Pharmaceuticals announces Presentation of New Satraplatin ...  Feb 27, 2006
...- New preclinical data on efficacy of satraplatin in prostate cancer cells and with Taxotere also presented - In December, a rolling submission of an NDA with ... - PR Newswire (press release),

ASCO Prostate: Intermittent Chemotherapy Controls Androgen ...  Feb 28, 2006
The 56 patients were culled from 250 men who participated in the phase III randomized ASCENT trial, which compared Taxotere (docetaxel) plus a high-dose ... - MedPage Today,

Treatment “Holidaysâ€? Effective in Hormone-Refractory Prostate ...  Mar 1, 2006
...included a subgroup of 45 patients involved in a larger clinical trial referred to as the ASCENT trial in which treatment with Taxotere® (docetaxel) plus ... - Cancer Consultants (press release),

Cytogen's Quadramet Helps Lower PSA  Feb 27, 2006
In a mid-stage study, the use of Quadramet combined with Sanofi-Aventis SA's Taxotere was shown to lower levels of prostate specific antigen, or PSA, by more ... - Houston Chronicle,

GPC Biotech Presents New Satraplatin Clinical Data from ...  Feb 27, 2006
Seven patients in the study had hormone-refractory prostate cancer (HRPC), and all of the HRPC patients had received Taxotere(r) (docetaxel), with a median of ... - PharmaLive.com (press release),

Xeloda Expands Options in Adjuvant Treatment of Breast Cancer ...  Feb 21, 2006
R)) in the metastatic setting, its association with minimal myelosuppression and alopecia, and the lack of increased toxicity when added to taxotere all point ... - DG News

Information on knee pain, breast cancer drugs and protecting bones  Feb 22, 2006
The New England Journal of Medicine reports on a study comparing the drugs Taxotere and Navelbine in early breast cancer. A study ... - 7Online.com,

Pharmion Corporation Announces New Satraplatin Clinical Data From ...  Feb 27, 2006
...* New Preclinical Data on Efficacy of Satraplatin in Prostate Cancer Cells and With Taxotere(R) Also Presented BOULDER, Colo., Feb. ... - PR Newswire (press release),

Drug May Help Curb Breast Cancer  Feb 22, 2006
The researchers randomly assigned half of those women to take Herceptin for nine weeks, along with chemotherapy drugs Taxotere or Navelbine. ... - WebMD

GPC Biotech Presents New Satraplatin Clinical Data From ...  Feb 27, 2006
New Preclinical Data on Efficacy of Satraplatin in Prostate Cancer Cells And With Taxotere(R) Also Presented MARTINSRIED/MUNICH, Germany, Feb. ... - PR Newswire (press release),

Breast Cancer Drugs Limit Post-Surgery Recurrence  Feb 22, 2006
22 (HealthDay News) -- A new head-to-head study finds the chemotherapy drug docetaxel (Taxotere) beating another, vinorelbine (Navelbine), in helping extend ... - Forbes

Breast meds limit recurrence  Feb 23, 2006
A new head-to-head study finds the chemotherapy drug docetaxel (Taxotere) beating another, vinorelbine (Navelbine), in helping extend patient survival after ... - Health24.com,

Trails to detect effective breast cancer drugs that reduces ...  Feb 23, 2006
...cancer surgery. The chemotherapy drugs docetaxel (Taxotere) and vinorelbine (Navelbine) are tested to analyze the outcomes. It was ... - MedIndia,

Sanofi-Aventis' Battered Charm  Mar 1, 2006
Key brands, such as Plavix, Taxotere and Eloxatin oncology treatments, Lantus antidiabetes agent, and Avapro -- an antihypertensive -- will likely drive the ... - BusinessWeek

MRI Contrast Agent Enhances Chemotherapy's Cancer Killing  Feb 15, 2006
Cancer Institute. The drugs were Taxol (paclitaxel), Taxotere (docetaxel), Eloxatin (oxaliplatin), and 5-fluorouracil (5FU). In ... - MedPage Today,

Positive Findings From Clinical Studies of QUADRAMET(R) in ...  Feb 27, 2006
This phase II study was designed to evaluate the tolerability and efficacy of QUADRAMET in combination with docetaxel (Taxotere(R), Aventis Pharmaceuticals, a ... - International News Service,

Cell Genesys gives promising prostate cancer trial update  Feb 28, 2006
...median survival of 18.9 months for metastatic hormone-refractory prostate cancer patients treated with Sanofi-Aventis' Taxotere (docetaxel) chemotherapy plus ... - Pharmaceutical Business Review

YM's Breast-Cancer Drug is Fast-Tracked  Feb 13, 2006
YM said it is also collaborating with Sanofi-Aventis on a phase 2 study that combine tesmilifene with Taxotere for the treatment of metastatic and recurrent ... - International News Service,

YM BioSciences breast cancer drug fast-tracked by FDA  Feb 14, 2006
YM is also initiating a phase II trial in collaboration with Sanofi-Aventis combining tesmilifene with Taxotere for the treatment of metastatic and recurrent ... - Pharmaceutical Business Review

American Pharmaceutical Partners and American BioScience Announce ...  Feb 14, 2006
Earlier, at Aventis and Rhone-Poulenc Rorer he held senior management positions with a variety of responsibilities related to Taxotere(R), including the ... - PR Newswire (press release),

Sanofi to Introduce Acomplia as Diet Pill This Year (Update3)  Feb 23, 2006
Products that are at risk include the cancer drugs Eloxatin and Taxotere as well as Plavix and Avapro, for high blood pressure. ... - Bloomberg

YM BioSciences reports second quarter 2006 operational and ...  Feb 10, 2006
...into a collaborative agreement with Sanofi-Aventis to investigate the effect of combining tesmilifene and the blockbuster cancer drug Taxotere(R) (docetaxel ... - MSN Money

GPC says satraplatin well tolerated in Phase I  Feb 27, 2006
It said of the 17 patients, seven had hormone refractory prostate cancer, and had received Taxotere, a chemotherapy treatment for some types of cancer ... - Reuters

Adjuvant Docetaxel More Effective Than Vinorelbine for Early ...  Feb 23, 2006
Patients were randomly assigned to treatment with docetaxel (Taxotere, Sanofi-Aventis) 100 mg per square meter of body-surface area on day 1 of three 21-day ... - Cancerpage.com,

Cancer, AIDS drugs may get cheaper after Budget  Feb 22, 2006
Aventis Pharma, which sells its breast, prostate and non-small cell lung cancer drug Taxotere (chemical name Irinotecan) for Rs 8,250 for a 20-mg vial and ... - Economic Times,

Clean-up sparks lifesaving plan  Feb 20, 2006
...heard about the yew trees at St Mary's being cut back we suggested collecting all future cuttings to be sent off for use in drugs such as Docetaxel and Taxotere ... - Blyth Wansbeck Today,

Sanofi expects Acomplia launch in 06; profits up  Feb 24, 2006
...to its two top-selling drugs, Plavix (clopidogrel) and Lovenox (enoxaparin), while other big sellers such as the cancer drugs Taxotere (docetaxel) and Eloxatin ... - Pharma Times (subscription),

Agency discloses '04 medicine deaths  Jan 31, 2006
Of the 63 deaths, 12 were due to interstitial pneumonia from Iressa, a drug used for lung cancer, five from effects of the cancer drug Taxotere and four from ... - The Japan Times,

Instead of spending $150,000 on a house, I'll be spending it on my ...  Feb 18, 2006
She has had a double mastectomy and needs three courses of chemotherapy: the first is government funded; the second, using Taxotere, costs $26,000; the third ... - New Zealand Herald,

UPDATE 1-Novacea files for $75 million IPO  Feb 10, 2006
The company expects DN-101 to complement the leading AIPC treatment Taxotere, a drug from Sanofi-Aventis (SASY.PA: Quote, Profile, Research) approved for use ... - Reuters

Lung Cancer Drug Pipeline Update Lists All 243 Drugs for Lung ...  Feb 16, 2006
Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, Aventis' Taxotere (docetaxel), Bristol-Myers ... - Genetic Engineering News,

Cell Therapeutics: hoping for a rich performance  Feb 9, 2006
In addition, Cell Therapeutics may find the restricted NSCLC market tough to penetrate given stiff competition from Sanofi-Aventis' Taxotere and Eli Lilly's ... - Pharmaceutical Business Review

IP Chemotherapy Encouraged for Ovarian Cancer  Feb 13, 2006
...administration of both a platinum drug [cisplatin (Platinol®) or carboplatin (Paraplatin®)] and a taxane drug [paclitaxel (Taxol®) or docetaxel (Taxotere ... - CancerWise

YM BioSciences receives FDA fast track designation for tesmilifene ...  Feb 13, 2006
YM is also initiating a Phase II trial in collaboration with Sanofi- Aventis combining tesmilifene with Taxotere for the treatment of metastatic and recurrent ... - Yahoo! News (press release)

Study Confirms Better Quality of Life with Paraplatin® than ...  Feb 7, 2006
...of Paraplatin and Taxol has become the standard treatment for women with advanced ovarian cancer and more recently, the combination of Taxotere (docetaxel) and ... - Cancer Consultants (press release),

Genomic Health Announces Fourth Quarter and Year-end 2005 ...  Feb 13, 2006
...the ability of gene expression in fixed- paraffin-embedded tissues to predict the likelihood of response to adjuvant chemotherapy, including Taxotere(R), in ... - PR Newswire (press release),

Nereus Pharmaceuticals Appoints Dr. Gary Shearman Chairman of the ...  Feb 15, 2006
...and implemented global drug development and regulatory strategies resulting in over twenty product approvals, including major oncology (Taxotere and Campto ... - Drug Newswire (press release),

Favrille Reports Fourth Quarter and Year End 2005 Financial ...  Feb 9, 2006
...the last 10 years specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin®, Fludara® and Taxotere ... - Yahoo! News (press release)

Favrille Reports Fourth Quarter and Year End 2005 Financial ...  Feb 10, 2006
...specifically dedicated to commercializing oncology products and managing leading brands such as Rituxan, Herceptin(R), Fludara(R) and Taxotere(R). Conference ... - PR Newswire (press release),

Genomic Health Announces Fourth Quarter and Year-end 2005 ...  Feb 13, 2006
...of gene expression in fixed- paraffin-embedded tissues to predict the likelihood of response to adjuvant chemotherapy, including Taxotere®, in patients with ... - Yahoo! News (press release)